outperform price
earn report chang price
msd top-line outlook reit o/p
evrisi thesi updat everi
alway gotten pushback either segment perform
cyno gyn rev popular punch
bag question around sustain breast health
room debat everi segment even
around order trend capital-expenditure environ provid visibl
bh strength annual deal also aid
org growth mdx grown hsd dd
trend sustain given new product
momentum get pushback gm
st think underli remain strong headlin
attribut fx hw gm includ bp
one timer impli came
seem in-line given fx hit would like
remind investor set deliv ep growth
year om provid ampl
proof underli execut right msd
organ thesi margin normal impli dd ep
trajectori conclus reiter outperform
rate share rais pt
price-to-earnings given confid execut
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
like
top-line rais guidanc
dx show across board strength ex-blood screen ou strength impli share gain
gyn grew msd first time year
like
light due fx come wors expect
us medic aesthet improv still neg territori
initi revenu guid street mid point
us biz acceler ex-blood led breast health molecular dx well us surgic busi
would higher ex-latam due polit challeng mostli bh busi
mm faxitron rev breast imag focal intervent breast
driven strong sale geniu system well intellig clariti hd smartcurv
benefit focu portfolio sell well acquir focal busi
acquisit ssi mm accret revenu slightli dilut ep
ssi ldd grower mm contribut mm
molecular remain growth driver ou base product
sale aptima women health assay chlamydia gonorrhea hpv trichomona strong
blood screen declin total mm mm
panther placement continu quarter throughput keep increas exist box
growth strength new leadership drive steadi cadenc
myosur sale forc get stronger led healthi growth
built fluid manag system omni hysteropscop
new product way intern via licens
us sale stabil post third growth sequenti
gm hit strong usd trade tariff increas servic cost
fx got wors issu dissip margin improv new product sale cost
mm share repurchas mm
mm remain buy-back author
net leverag ratio
rais guidanc fx mm mm vs prior mm
rais blood screen contribut vs prior
blood screen declin level
medic aesthet season weaker summer month
maintain middl guid investor expect
fewer sell day impact minim due independ day
 typic unlik exceed hunt mm rang
valuat methodolog base mix discount cash flow analysi rel valuat multipl
failur execut cyno weigh sentiment multipl higher expect declin mammographi
margin expans thesi doesnt play due higher invest turn around busi
articl articl
time dissemin juli
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
